- ISIN
- US5288723027
- CUSIP
- 528872302
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Apr 7, 2000
Highlights
- Market Cap
- $1.03B
- Enterprise Value
- $988.00M
- EPS (TTM)
- -$0.07
- Total Revenue (TTM)
- $69.64M
- Gross Profit (TTM)
- $69.00M
- EBITDA (TTM)
- -$20.38M
- Year Range
- $1.02 - $2.68
- Target Price
- $6.00
- ROA (TTM)
- -9.71%
- ROE (TTM)
- -12.86%
- Avg. Volume (1M)
- 3M
- Avg. Volume Value (1M)
- $6.21M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
LXRX Performance Chart
Lexicon Pharmaceuticals, Inc. (LXRX) is up 100.9% since the beginning of the year. At $2 per share, LXRX is trading 13.8% below its 52-week high of $3. Investors who bought $1,000 worth of LXRX shares 5 years ago would now be looking at an investment worth $653.
Loading charts...
Compare this symbol against anything
Returns By Period
Lexicon Pharmaceuticals, Inc. (LXRX) has returned 100.87% so far this year and 115.89% over the past 12 months. Over the last ten years, LXRX has returned -17.59% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
Lexicon Pharmaceuticals, Inc.
- 1D
- -1.28%
- 1M
- -0.43%
- 6M
- 99.14%
- YTD
- 100.87%
- 1Y
- 115.89%
- 3Y*
- 5.99%
- 5Y*
- -8.18%
- 10Y*
- -17.59%
- ALL TIME*
- -14.75%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
LXRX Monthly Returns History
Based on dividend-adjusted daily data since Apr 7, 2000, LXRX's average daily return is +0.08%, while the average monthly return is +1.39%. At this rate, an investment would double in approximately 4.2 years.
Historically, 47% of months were positive and 53% were negative. The best month was Jun 2000 with a return of +250.4%, while the worst month was Jul 2019 at -78.5%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 5 months.
On a daily basis, LXRX closed higher 46% of trading days. The best single day was Jan 14, 2021 with a return of +105.4%, while the worst single day was Jul 29, 2019 at -70.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.87% | 26.72% | 6.12% | 3.21% | 35.40% | 10.09% | -3.75% | 100.87% | |||||
| 2025 | 2.40% | -7.50% | -34.12% | 58.59% | -14.26% | 50.93% | 13.14% | 2.80% | 22.73% | 2.22% | 3.62% | -19.58% | 55.72% |
| 2024 | 22.22% | 33.16% | -3.61% | -35.83% | 10.39% | -1.18% | 33.93% | -23.11% | -9.25% | 24.20% | -58.97% | -7.69% | -51.73% |
| 2023 | 17.28% | 0.45% | 8.00% | -1.65% | 38.08% | -30.61% | -12.23% | -14.43% | -36.63% | 13.76% | -14.52% | 44.34% | -19.90% |
| 2022 | -19.54% | -34.70% | 0.97% | -13.40% | -2.21% | 5.08% | 27.96% | 15.55% | -12.73% | -10.42% | -0.47% | -10.75% | -51.52% |
| 2021 | 131.29% | -9.10% | -18.36% | -17.21% | -9.67% | 4.56% | -22.88% | 33.33% | 1.91% | 9.98% | -13.42% | -13.97% | 15.20% |
Benchmark Metrics
Lexicon Pharmaceuticals, Inc. has an annualized alpha of 9.92%, beta of 1.49, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since April 07, 2000.
- This stock participated in 182.80% of S&P 500 Index downside but only 115.15% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.11 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 9.92%
- Beta
- 1.49
- R²
- 0.11
- Upside Capture
- 115.15%
- Downside Capture
- 182.80%
Return for Risk
Risk / Return Rank
LXRX ranks 85 for risk / return — above 85% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Lexicon Pharmaceuticals, Inc. (LXRX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LXRX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.08 | ||
| Sortino ratioReturn per unit of downside risk | +0.28 | ||
| Omega ratioGain probability vs. loss probability | 1.27 | 1.25 | +0.02 |
| Calmar ratioReturn relative to maximum drawdown | 3.42 | 2.00 | +1.42 |
| Martin ratioReturn relative to average drawdown | 7.67 | 8.49 | -0.82 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Lexicon Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Lexicon Pharmaceuticals, Inc. was 99.91%, occurring on Mar 3, 2025. The portfolio has not yet recovered.
The current Lexicon Pharmaceuticals, Inc. drawdown is 99.30%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.91%Mar 2025 | 24y 7mo | — | 26y 16dJul 2000 - now | 2025 selloff2025 |
-58.52%Apr 2000 | 20d | 1mo 25d | 2mo 15dApr 2000 - Jun 2000 | Dot-com crash2000–2002 |
-15.33%Jul 2000 | 2d | 7d | 9dJul 2000 - Jul 2000 | Dot-com crash2000–2002 |
-8.08%Jun 2000 | 1d | 1d | 1dJun 2000 - Jun 2000 | Dot-com crash2000–2002 |
-5.17%Jun 2000 | 1d | 6d | 6dJun 2000 - Jul 2000 | Dot-com crash2000–2002 |
Drawdown Indicators
| LXRX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.91% | -56.78% | -43.13% |
Max Drawdown (1Y)Largest decline over 1 year | -34.09% | -9.10% | -24.99% |
Max Drawdown (3Y)Largest decline over 3 years | -91.83% | -18.90% | -72.93% |
Max Drawdown (5Y)Largest decline over 5 years | -95.25% | -25.43% | -69.82% |
Max Drawdown (10Y)Largest decline over 10 years | -98.48% | -33.92% | -64.56% |
Current DrawdownCurrent decline from peak | -99.30% | -1.58% | -97.72% |
Average DrawdownAverage peak-to-trough decline | -93.30% | -10.70% | -82.60% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.17% | 2.14% | +13.03% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Lexicon Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Lexicon Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for LXRX relative to other companies in the Biotechnology industry. Currently, LXRX has a P/S ratio of 12.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for LXRX in comparison with other companies in the Biotechnology industry. Currently, LXRX has a P/B value of 4.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with LXRX
Add Lexicon Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with LXRX